ACCORD HLTHCARE
GenericsACCORD HLTHCARE is a generic drug manufacturer focused on Oncology, Cardiovascular, Neurology.
ACCORD HLTHCARE's Key Drugs
ACCORD HLTHCARE's core commercial portfolio centers on PRASUGREL, CISATRACURIUM BESYLATE PRESERVATIVE FREE, OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE, spanning Oncology and Cardiovascular — its most strategically important drugs approved in the last 15 years.
Thrombotic Cardiovascular Events
Tracheal intubation
Hypertension
Hypertension
ACCORD HLTHCARE's Recent FDA Approvals
ACCORD HLTHCARE secured 4 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
ACCORD HLTHCARE's Therapeutic Areas
ACCORD HLTHCARE's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ACCORD HLTHCARE's Top Competitors
ACCORD HLTHCARE's closest competitors by therapeutic-area and drug-target overlap include Bristol-Myers Squibb, Pfizer, and GE HEALTHCARE. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ACCORD HLTHCARE Pipeline Snapshot
Active clinical trials for ACCORD HLTHCARE across all therapeutic areas, from ClinicalTrials.gov.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • PRASUGREL leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Oncology pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (4)
Discontinued (0)
Company Info
- First Approval
- 1972-09-20
- Latest
- 2026-06-09
- Applications
- 163